"It's very hard for her to go out to a lot of places in public right now because her lungs are so compromised. The medicine ...

Did you see this? Nearly 1 in 10 Americans have asthma. Here's what causes it.

Hundreds of Lowcountry moms danced the night away all in support of research to support a treatment for a genetic disorder.

A new inhalable gene therapy for cystic fibrosis (CF) has entered Phase I clinical trials, a major milestone on the journey ...

Boehringer Ingelheim, IP Group, the UK Respiratory Gene Therapy Consortium (GTC) 1 and OXB, 1 today announce the start of LENTICLAIR TM 1, a Phase I/II trial of BI 3720931, a novel, first-in-class, ...

An inhalable medicine with the potential to improve lung disease in people with cystic fibrosis, irrespective of their ...

An inhaled gene therapy for cystic fibrosis developed by Boehringer Ingelheim is due to start clinical testing shortly, hoping to become a first-in-class treatment for the genetic disorder.

The global Cystic Fibrosis Market is valued at $10.4 billion in 2023 and is projected to reach $55.4 billion by 2032, ...

Once-daily vanzacaftor-tezacaftor-deutivacaftor was safe and well-tolerated in children with cystic fibrosis, while ...

Findings from a new study highlight key differences in the gut microbiome of infants with cystic fibrosis (CF) compared to that of healthy infants, and how these alterations may adversely affect their ...